JERUSALEM--(BUSINESS WIRE)--May. 9, 2012--
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today issued updated
dial-in information regarding the conference call to be held today, May
9, 2012 at 8:30 a.m. ET to discuss its first quarter 2012 results.
The call will be webcast and can be accessed through the Company's
website at www.tevapharm.com,
or by dialling in to 866.652.8972 or 800.994.4498 (U.S.), 0.800.032.3367
(UK), or 972.3.9180687 (Israel and International). Following the
conclusion of the call, a replay of the webcast will be available within
24 hours at the Company's website at www.tevapharm.com.
A replay of the call will also be available until May 16, 2012, at 11:59
p.m. ET, by calling 1.877.456.0009 (U.S. and Canada), 0.800.028.6837
(UK) or 972.3.9255921 (Israel and International).
About Teva
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) is a leading global
pharmaceutical company, committed to increasing access to high-quality
healthcare by developing, producing and marketing affordable generic
drugs as well as innovative and specialty pharmaceuticals and active
pharmaceutical ingredients. Headquartered in Israel, Teva is the world's
leading generic drug maker, with a global product portfolio of more than
1,300 molecules and a direct presence in about 60 countries. Teva's
branded businesses focus on CNS, oncology, pain, respiratory and women's
health therapeutic areas as well as biologics. Teva currently employs
approximately 46,000 people around the world and reached $18.3 billion
in net revenues in 2011.
Teva’s Safe Harbor Statement under the U.S. Private Securities
Litigation Reform Act of 1995:
This release contains forward-looking statements, which express the
current beliefs and expectations of management. Such statements are
based on management’s current beliefs and expectations and involve a
number of known and unknown risks and uncertainties that could cause our
future results, performance or achievements to differ significantly from
the results, performance or achievements expressed or implied by such
forward-looking statements. Important factors that could cause or
contribute to such differences include risks relating to: our ability to
develop and commercialize additional pharmaceutical products,
competition for our innovative products, especially Copaxone® (including
competition from innovative orally-administered alternatives, as well as
from potential generic equivalents), competition for our generic
products (including from other pharmaceutical companies and as a result
of increased governmental pricing pressures), competition for our
specialty pharmaceutical businesses, our ability to achieve expected
results through our innovative R&D efforts, the effectiveness of our
patents and other protections for innovative products, decreasing
opportunities to obtain U.S. market exclusivity for significant new
generic products, our ability to identify, consummate and successfully
integrate acquisitions (including the acquisition of Cephalon), the
effects of increased leverage as a result of the acquisition of
Cephalon, the extent to which any manufacturing or quality control
problems damage our reputation for high quality production and require
costly remediation, our potential exposure to product liability claims
to the extent not covered by insurance, increased government scrutiny in
both the U.S. and Europe of our agreements with brand companies,
potential liability for sales of generic products prior to a final
resolution of outstanding patent litigation, including that relating to
the generic version of Protonix®, our exposure to currency fluctuations
and restrictions as well as credit risks, the effects of reforms in
healthcare regulation and pharmaceutical pricing and reimbursement, any
failures to comply with complex Medicare and Medicaid reporting and
payment obligations, governmental investigations into sales and
marketing practices (particularly for our specialty pharmaceutical
products), uncertainties surrounding the legislative and regulatory
pathway for the registration and approval of biotechnology-based
products, adverse effects of political or economical instability, major
hostilities or acts of terrorism on our significant worldwide
operations, interruptions in our supply chain or problems with our
information technology systems that adversely affect our complex
manufacturing processes, any failure to retain key personnel (including
Cephalon employees) or to attract additional executive and managerial
talent, the impact of continuing consolidation of our distributors and
customers, variations in patent laws that may adversely affect our
ability to manufacture our products in the most efficient manner,
potentially significant impairments of intangible assets and goodwill,
potential increases in tax liabilities, the termination or expiration of
governmental programs or tax benefits, environmental risks and other
factors that are discussed in our Annual Report on Form 20-F for the
year ended December 31, 2011 and in our other filings with the U.S.
Securities and Exchange Commission.
Source: Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
IR:
United States
Kevin
C. Mannix, 215-591-8912
or
Israel
Tomer Amitai, 972 (3)
926-7656
or
PR:
United States
Denise Bradley,
215-591-8974
or
Israel
Shir Altay-Hagoel, 972 (3) 926-7590